Literature DB >> 11118387

Type 1/Type 2 immunity in infectious diseases.

B Spellberg1, J E Edwards.   

Abstract

T helper type 1 (Th1) lymphocytes secrete secrete interleukin (IL)-2, interferon-gamma, and lymphotoxin-alpha and stimulate type 1 immunity, which is characterized by intense phagocytic activity. Conversely, Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is characterized by high antibody titers. Type 1 and type 2 immunity are not strictly synonymous with cell-mediated and humoral immunity, because Th1 cells also stimulate moderate levels of antibody production, whereas Th2 cells actively suppress phagocytosis. For most infections, save those caused by large eukaryotic pathogens, type 1 immunity is protective, whereas type 2 responses assist with the resolution of cell-mediated inflammation. Severe systemic stress, immunosuppression, or overwhelming microbial inoculation causes the immune system to mount a type 2 response to an infection normally controlled by type 1 immunity. In such cases, administration of antimicrobial chemotherapy and exogenous cytokines restores systemic balance, which allows successful immune responses to clear the infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118387     DOI: 10.1086/317537

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  234 in total

1.  Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans?

Authors:  M Sandmand; H Bruunsgaard; K Kemp; K Andersen-Ranberg; A N Pedersen; P Skinhøj; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 2.  Immunopathogenesis of Haemophilus ducreyi infection (chancroid).

Authors:  Stanley M Spinola; Margaret E Bauer; Robert S Munson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

3.  Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection.

Authors:  Stanley M Spinola; Cliffton T H Bong; Andrew L Faber; Kate R Fortney; Stacy L Bennett; Carisa A Townsend; Beth E Zwickl; Steven D Billings; Tricia L Humphreys; Margaret E Bauer; Barry P Katz
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

4.  Impact of sex and ozone exposure on the course of pneumonia in wild type and SP-A (-/-) mice.

Authors:  Anatoly N Mikerov; Sanmei Hu; Faryal Durrani; Xiaozhuang Gan; Guirong Wang; Todd M Umstead; David S Phelps; Joanna Floros
Journal:  Microb Pathog       Date:  2012-01-20       Impact factor: 3.738

5.  Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer.

Authors:  Xiaoxiang Guan; Erich M Sturgis; Dapeng Lei; Zhensheng Liu; Kristina R Dahlstrom; Qingyi Wei; Guojun Li
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

6.  Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.

Authors:  A Singh; A Mohan; A B Dey; D K Mitra
Journal:  Clin Exp Immunol       Date:  2016-11-24       Impact factor: 4.330

Review 7.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Characterization of immune response elicited by the recombinant outer membrane protein OmpF of Aeromonas hydrophila, a potential vaccine candidate in murine model.

Authors:  Sunita Kumari Yadav; Pramod Kumar Sahoo; Aparna Dixit
Journal:  Mol Biol Rep       Date:  2014-01-17       Impact factor: 2.316

9.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis.

Authors:  Wei Xin; Soo-Young Wanda; Yuhua Li; Shifeng Wang; Hua Mo; Roy Curtiss
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.